US government will test ibogaine as an addiction treatment

When one typically thinks of psychedelics, the word “trip” is top of mind. Ibogaine has proven effective at treating addiction to tobacco, alcohol, and drugs. Yet, for those naysayers that continue to doubt the treatment based on the fact a “trip” is part of the equation, Will Yakowicz delivers a fascinating story on professor David Olson and his pursuit of a “no-trip” treatment.

In addition to being a faculty member at the University of California at Davis, Olson is also the co-founder of Delix, a company attempting to remove the “trip” from psychedelics while still preserving their therapeutic components. The company’s Delix-7 is said to do just that with ibogaine.

Olson is partial to a theory that the psychedelic trip is not necessary to treat the common addictions that ibogaine treats. The most important part, according to Olson, is the development of neuroplasticity which helps the brain form new neural connections in a positive way.

More research is needed, but this is indeed a promising line of research.

Read the full article here: https://www.forbes.com/sites/willyakowicz/2021/12/07/us-government-will-test-ibogaine-as-an-addiction-treatment